S. Smith

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.

T. Zimmerman, R. Larson, Dingcai Cao, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous and allogeneic transplantation for aggressive NHL.

Sonali M. Smith, K. van Besien, K. Besien, 2002, Cytotherapy.

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Sonali M. Smith, L. Gordon, T. Habermann, 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

Sonali M. Smith, T. Zimmerman, R. Larson, 2007, Bone Marrow Transplantation.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.

Sonali M. Smith, C. Flowers, B. Woda, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Recombinant interferon-α2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691

M. Oken, G. Petroni, B. Parker, 2009, Leukemia & lymphoma.

A phase II study of Epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin’s lymphomas

E. Vokes, T. Karrison, P. Stiff, 2005 .

Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary.

E. Vokes, A. Argiris, D. Haraf, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

J. Friedberg, J. Leonard, M. Shipp, 2023, Hematological Oncology.

Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.

B. Cheson, S. Parasuraman, P. Rosen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.